Seelos Therapeutics   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: New York NY United States (2016)

Organization Overview

First Clinical Trial
2020
NCT04669665
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Seelos Therapeutics, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

Key: Seelos Therapeutics (0) Acquired (1)

trehalose (9 trials)

Drugs in Phase 2 Trials (3)

Key: Seelos Therapeutics (1) Acquired (2)

alprostadil (prostin) (1 trial)

fispemifene (1 trial)

ketamine (ketalar) (1 trial)

Drugs in Phase 1 Trials (2)

Key: Seelos Therapeutics (0) Acquired (2)

sodium chloride (1 trial)

terbinafine (lamisil) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Depression (Phase 2)

Depressive Disorder (Phase 2)

Depressive Disorder, Major (Phase 2)

Disease (Phase 2)

Suicide (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 13
  • # of Trial APIs: 6